Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration

Dow Jones received a payment from EQS/DGAP to publish this press release.

Hardman & Co Research 
Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to 
registration 
 
21-May-2018 / 12:25 GMT/BST 
 
*Hardman & Co Research: Opening the door to registration* 
 
AGY is a long-established specialist in the prevention, diagnosis and 
treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy 
immunotherapy (SCIT), continues to gain market share despite being available 
in the EU only on a 'Named Patient' basis. As part of a programme designed to 
get PQ Grass formally approved in both Europe and the US, AGY has announced 
positive results from its Phase II dose-ranging clinical trial. It has 
identified the optimum dose as needed to move forward into the final Phase III 
efficacy trials, and to become the first SCIT product to be registered in 
these important pharmaceutical markets. 
 
Please click here for the full report: 
 
http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics- 
documents/21.05.18-opening-the-door-to-registration.pdf [1] 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*Hardman & Co Research can still be accessed for free after MiFID II. Please 
*click here [2] *to read the statement.* 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the UK and abroad with outstanding research, investor engagement 
programmes and advisory services. Some of our notes have been commissioned by 
the company which is the subject of the note; this is clearly stated in the 
disclaimer where this is the case. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
687981 21-May-2018 
 
 
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ac430a02167a66febabe3dd1a4f44d7e&application_id=687981&site_id=vwd&application_name=news 
2: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=687981&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

May 21, 2018 07:25 ET (11:25 GMT)